• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉丁美洲脊髓灰质炎现状。

Current status of poliomyelitis in Latin America.

机构信息

Facultad de Medicina, Universidad Metropolitana de Santos, São Paulo, Brasil.

Facultad de Ciencias Médicas, Universidad Nacional La Plata, Buenos Aires, Argentina.

出版信息

Rev Chilena Infectol. 2020 Dec;37(6):701-709. doi: 10.4067/S0716-10182020000600701.

DOI:10.4067/S0716-10182020000600701
PMID:33844811
Abstract

Oral poliovirus vaccine (OPV) has been instrumental in controlling the polio epidemic, and stands out for its safety, efficacy, ease of oral administration, and low cost. However, despite these advantages, as it is a live attenuated virus vaccine, there is the possibility of mutations that confer neurovirulence. Therefore, surveillance for acute flaccid paralysis (AFP) is important, whether associated with live vaccines (VAPP) or vaccine-derived viruses (VDPV). In this review we present important data from Latin America in recent years, where data on VDPV of community transmission, of ambiguous origin and associated with immunodeficiencies are reviewed. Due to the presence of VDPV, it is important to strengthen the epidemiological surveillance system for AFP, with data much lower than those recommended in recent years in the Americas. Additionally, it is essential to improve vaccination coverage to reduce the number of infants at risk of acquiring poliomyelitis. Consequently, we present the vaccination coverage rates with the inactivated vaccine against poliovirus (IPV) in the region and analyze the vaccination programs against poliomyelitis in accordance with the recommendations of the Latin American Society of Pediatric Infectious Diseases (SLIPE; minimum 3 doses of IPV) and the WHO Strategic Advisory Expert Group (SAGE) on Immunization (minimum 2 doses of IPV). The study concludes with recommendations from the authors for the change from OPV to exclusive use of IPV, to increase vaccination coverage and to strengthen surveillance for AFP in the region.

摘要

口服脊髓灰质炎疫苗(OPV)在控制脊髓灰质炎疫情方面发挥了重要作用,其安全性、有效性、口服给药的便利性和低成本尤为突出。然而,尽管具有这些优势,但由于它是一种减毒活病毒疫苗,存在突变获得神经毒力的可能性。因此,急性弛缓性麻痹(AFP)的监测非常重要,无论是与活疫苗(VAPP)还是疫苗衍生病毒(VDPV)相关。在本次综述中,我们呈现了近年来拉丁美洲的重要数据,其中包括社区传播、来源不明和与免疫缺陷相关的 VDPV 的数据。由于存在 VDPV,加强 AFP 的流行病学监测系统非常重要,而该地区的监测数据远低于近年来美洲的推荐值。此外,提高疫苗接种覆盖率以减少感染脊髓灰质炎风险的婴儿数量至关重要。因此,我们呈现了该地区针对脊髓灰质炎的灭活疫苗(IPV)的接种覆盖率,并根据拉丁美洲儿科学会感染性疾病分会(SLIPE;至少 3 剂 IPV)和世界卫生组织免疫战略咨询专家组(SAGE)的建议分析了脊髓灰质炎免疫接种计划(至少 2 剂 IPV)。该研究根据作者的建议得出结论,建议从 OPV 转变为仅使用 IPV,以提高疫苗接种覆盖率并加强该地区 AFP 的监测。

相似文献

1
Current status of poliomyelitis in Latin America.拉丁美洲脊髓灰质炎现状。
Rev Chilena Infectol. 2020 Dec;37(6):701-709. doi: 10.4067/S0716-10182020000600701.
2
The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).拉丁美洲更换灭活脊髓灰质炎疫苗面临的挑战:拉丁美洲儿科传染病学会(SLIPE)声明
Rev Chilena Infectol. 2014 Oct;31(5):590-603. doi: 10.4067/S0716-10182014000500012.
3
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.用于预防脊髓灰质炎的序贯灭活脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎减毒活疫苗(OPV)
Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2.
4
[Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule].[关于在拉丁美洲儿童免疫规划中引入灭活脊髓灰质炎疫苗分剂量的可能性的说明]
Rev Chilena Infectol. 2018 Aug;35(4):395-402. doi: 10.4067/s0716-10182018000400395.
5
Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.引入灭活脊髓灰质炎疫苗以推进脊髓灰质炎根除终局战略计划;中国杭州,2010 - 2014年
Vaccine. 2017 Mar 1;35(9):1281-1286. doi: 10.1016/j.vaccine.2017.01.034. Epub 2017 Feb 1.
6
Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.关于在拉丁美洲儿童免疫规划中引入灭活脊髓灰质炎疫苗分次剂量的可能性的说明。
Rev Chilena Infectol. 2019 Feb;36(1):83-90. doi: 10.4067/S0716-10182019000100083.
7
Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).美国的脊髓灰质炎预防:采用先接种灭活脊髓灰质炎病毒疫苗后接种口服脊髓灰质炎病毒疫苗的序贯接种程序。免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 1997 Jan 24;46(RR-3):1-25.
8
Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.1991年至1998年脊髓灰质炎疫苗不良事件监测:灭活脊髓灰质炎疫苗随后接种口服脊髓灰质炎疫苗的序贯接种方案的影响
Pediatrics. 2001 May;107(5):E83. doi: 10.1542/peds.107.5.e83.
9
Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.脊髓灰质炎疫苗。全球根除脊髓灰质炎的进展以及美国常规免疫接种建议的变化。
Pediatr Clin North Am. 2000 Apr;47(2):287-308. doi: 10.1016/s0031-3955(05)70208-x.
10
Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).美国的脊髓灰质炎预防。免疫实践咨询委员会(ACIP)的最新建议。
MMWR Recomm Rep. 2000 May 9;49(RR-5):1-22; quiz CE1-7.

引用本文的文献

1
Polio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.脊髓灰质炎流行病学:新冠疫情后根除脊髓灰质炎的策略与挑战
Vaccines (Basel). 2024 Nov 26;12(12):1323. doi: 10.3390/vaccines12121323.
2
Immune persistence after different polio sequential immunization schedules in Chinese infants.中国婴儿不同脊髓灰质炎序贯免疫程序后的免疫持久性
NPJ Vaccines. 2024 Feb 29;9(1):50. doi: 10.1038/s41541-024-00831-1.
3
Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
观察分析各种类型脊髓性肌萎缩症疫苗的免疫原性和安全性。
Inflammopharmacology. 2024 Apr;32(2):1025-1038. doi: 10.1007/s10787-023-01395-7. Epub 2024 Feb 3.
4
Vaccine-derived polio in Peru after 32 years of elimination: reflections on the routine childhood immunisation coverages.在秘鲁消除脊髓灰质炎32年后出现的疫苗衍生脊髓灰质炎:关于儿童常规免疫接种覆盖率的思考
Lancet Reg Health Am. 2023 Jun 14;23:100532. doi: 10.1016/j.lana.2023.100532. eCollection 2023 Jul.
5
Comparative Study on MNVT of OPV Type I and III Reference Products in Different Periods.口服脊髓灰质炎疫苗I型和III型参考品不同时期MNVT的比较研究
Diseases. 2023 Feb 8;11(1):28. doi: 10.3390/diseases11010028.
6
Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru.关于在哥伦比亚和秘鲁使用联合疫苗使婴儿疫苗接种计划现代化的建议。
Rev Panam Salud Publica. 2023 Jan 27;47:e24. doi: 10.26633/RPSP.2023.24. eCollection 2023.